---
category: news
title: "Why Shares of BioXcel Therapeutics Shot Up 25.4% This Week"
excerpt: "BioXcel Therapeutics is a clinical-stage biopharmaceutical with no review or marketed drugs yet. The company's stock rose more than $4 a share over the course of the week. It's expecting a decision by the FDA regarding its lead therapy by April 5."
publishedDateTime: 2022-03-24T23:00:00Z
originalUrl: "https://www.fool.com/investing/2022/03/24/why-shares-of-bioxcel-therapeutics-shot-up-254-thi/"
webUrl: "https://www.fool.com/investing/2022/03/24/why-shares-of-bioxcel-therapeutics-shot-up-254-thi/"
type: article
quality: 54
heat: 54
published: false

provider:
  name: The Motley Fool
  domain: fool.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/fool.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://g.foolcdn.com/editorial/images/671878/alzheimers.jpg"
    width: 2121
    height: 1414
    isCached: true

secured: "mVRlZtwIawLbsa7wSlVk0OPwmzmQq7Pcpf/SyQVnv/+VU2A6aMNjL3xZob5cWRBWvzmP04sZaozsd2/9ob0NwXy1paewaJjip8URaHmLzrfCo2srczNHX5dC1iECYuRtJbhqOR5FjNEC8Ou3J1DTFkFr5LqLTxylYZ7rst1jdHxdfg5ZfNmPAziQRPnSLxF3JVb8Za5ZBRrrWpJkMi06/59JKUYOr/66+s1SpvvE3fJ3JeXFmC6uE1lSIxZJYPBWSk5u0ohH0I94uf7HFK8Ou6U1sPtrQZGQG/UAz1sA1Y27/s4kjBpTOqcg6amLEtsKjm0pUpNACFbTtjHmSh4a1emw88mqzKlaKxhMnX3amyE=;DY1G5NRIztem1GolsMYj3g=="
---

